BEAM-101
Phase
Phase1 / Phase2Study status
Active not recruitingView details
Beam Therapeutics Inc.
IndicationSickle Cell Disease
Estimated study completion2028-02
Classification review pending
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
No verified development in tracked sources.
No upcoming event verified in tracked sources.
5 programs · 5 verified studies
| Company | Drug | Indication | Phase | Study status | Timing | Registry |
|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics Inc. | BEAM-101 | Sickle Cell Disease | Phase1 / Phase2 | Active not recruiting | Estimated study completion2028-02 | NCT05456880 |
| BEAM Beam Therapeutics Inc. | BEAM-103 | Healthy Subjects; Healthy Participant Study | Phase1 | Recruiting | Estimated study completion2026-05-29 | NCT07304791 |
| BEAM Beam Therapeutics Inc. | BEAM-201 | Lymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia | Phase1 / Phase2 | Active not recruiting | Estimated study completion2026-12 | NCT05885464 |
| BEAM Beam Therapeutics Inc. | BEAM-301: Single dose of BEAM-301 administered by IV | Glycogen Storage Disease Type Ia | Phase1 / Phase2 | Recruiting | Estimated study completion2027-12-30 | NCT06735755 |
| BEAM Beam Therapeutics Inc. | BEAM-302 | Alpha 1-Antitrypsin Deficiency | Phase1 / Phase2 | Recruiting | Estimated study completion2030-05 | NCT06389877 |
Phase
Phase1 / Phase2Study status
Active not recruitingBeam Therapeutics Inc.
IndicationSickle Cell Disease
Estimated study completion2028-02
Phase
Phase1Study status
RecruitingBeam Therapeutics Inc.
IndicationHealthy Subjects; Healthy Participant Study
Estimated study completion2026-05-29
Phase
Phase1 / Phase2Study status
Active not recruitingBeam Therapeutics Inc.
IndicationLymphoblastic Lymphoma; T-Cell Lymphoblastic Leukemia/Lymphoma; Lymphoblastic Leukemia
Estimated study completion2026-12
Phase
Phase1 / Phase2Study status
RecruitingBeam Therapeutics Inc.
IndicationGlycogen Storage Disease Type Ia
Estimated study completion2027-12-30
Phase
Phase1 / Phase2Study status
RecruitingBeam Therapeutics Inc.
IndicationAlpha 1-Antitrypsin Deficiency
Estimated study completion2030-05
2 unverified sponsor matches remain unlinked.
No verified developments in tracked sources.